Should I buy or sell Hims & Hers Health stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks .

What is Hims & Hers Health's stock price target for 2024?

9 brokers have issued twelve-month price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.08 in the next year. This suggests a possible upside of 37.3% from the stock's current price. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts .

How have HIMS shares performed in 2023?

Hims & Hers Health's stock was trading at $6.41 at the start of the year. Since then, HIMS stock has increased by 37.3% and is now trading at $8.80. View the best growth stocks for 2023 here .

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our HIMS earnings forecast .

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $226.70 million for the quarter, compared to analyst estimates of $220.08 million. Hims & Hers Health had a negative net margin of 4.50% and a negative trailing twelve-month return on equity of 11.22%. Hims & Hers Health's revenue for the quarter was up 56.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS.

What ETFs hold Hims & Hers Health's stock?

ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS) , Global X Telemedicine & Digital Health ETF (EDOC) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) , Amplify Online Retail ETF (IBUY) , Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) . iShares U.S. Healthcare Providers ETF (IHF) .

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Institutional Venture Management XVI LLC (3.66%), Institutional Venture Management XV LLC (3.66%), Jupiter Asset Management Ltd. (0.69%), Charles Schwab Investment Management Inc. (0.60%), Northern Trust Corp (0.55%) and Federated Hermes Inc. (0.49%). Insiders that own company stock include Alex Bard, Andrew Dudum , David B Wells, David B Wells , Irene Becklund, Jack Abraham , Jules A Maltz, Lynne Chou O'keefe, Melissa Baird , Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee . View institutional ownership trends .

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Hims & Hers Health (HIMS) Stock Price, News & Analysis

$8.80

+0.16 (+1.85%)

(As of 05:32 PM ET)

Compare

Today's Range: $8.64
▼
$8.88
50-Day Range: $5.76
▼
$8.90
52-Week Range: $5.65
▼
$12.34

Volume: 1.49 million shs
Average Volume: 2.96 million shs
Market Capitalization: $1.87 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.08

Hims & Hers Health MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 37.3% Upside
$12.08 Price Target
Short Interest: Bearish
12.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.12
Based on 13 Articles This Week
Insider Trading: Selling Shares
$785,410 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.13) to ($0.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

383rd out of 945 stocks

Offices & Clinics Of Medical Doctors Industry

2nd out of 6 stocks

3.3

Analyst's Opinion

Consensus Rating
Hims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.08, Hims & Hers Health has a forecasted upside of 37.3% from its current price of $8.80.
Amount of Analyst Coverage
Hims & Hers Health has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.75% of the float of Hims & Hers Health has been sold short.
Short Interest Ratio / Days to Cover
Hims & Hers Health has a short interest ratio ("days to cover") of 7.2.
Change versus previous month
Short interest in Hims & Hers Health has recently increased by 2.06%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Hims & Hers Health does not currently pay a dividend.
Dividend Growth
Hims & Hers Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HIMS.

2.8

News and Social Media Coverage

News Sentiment
Hims & Hers Health has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Hims & Hers Health this week, compared to 4 articles on an average week.
Search Interest
17 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.
MarketBeat Follows
7 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $785,410.00 in company stock.
Percentage Held by Insiders
31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.45% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Hims & Hers Health are expected to grow in the coming year, from ($0.13) to ($0.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hims & Hers Health is -51.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hims & Hers Health is -51.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hims & Hers Health has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Hims & Hers Health Stock (NYSE:HIMS)

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

HIMS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HIMS Stock News Headlines

December 4, 2023 | marketbeat.com

Ozempic vs. Mounjaro:: Battle of the bulge (HIMS)

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage

November 29, 2023 | marketbeat.com

Hims & Hers earnings highlight expanded personalized treatments

E-health and wellness platform operator Hims & Hers Inc. reported a stellar quarter of growth that highlighted its expanded line of personalized products

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

December 8, 2023 | americanbankingnews.com

Hims & Hers Health (NYSE:HIMS) Coverage Initiated by Analysts at Imperial Capital

December 7, 2023 | finance.yahoo.com

Insider Sell Alert: COO Melissa Baird Sells 27,399 Shares of Hims & Hers Health Inc (HIMS)

December 5, 2023 | markets.businessinsider.com

Bullish Outlook: Hims & Hers Health’s New Weight Loss Program Promises Long-Term Growth

December 5, 2023 | finance.yahoo.com

Insider Sell: CEO Andrew Dudum of Hims & Hers Health Inc Cashes Out Shares

December 5, 2023 | americanbankingnews.com

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 24,300 Shares of Stock

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

December 4, 2023 | finance.yahoo.com

Hims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss

December 2, 2023 | marketwatch.com

Hims Mental Health Review 2023: Results of Our Hands-On Testing

November 30, 2023 | seekingalpha.com

Hims & Hers Health: What Would The Author Of 100 Baggers Say?

November 27, 2023 | businessinsider.com

Why Hims & Hers won't prescribe Ozempic for now in its new weight-loss program

November 16, 2023 | msn.com

Is Hims & Hers Stock a Buy Now?

November 10, 2023 | forbes.com

Hims & Hers Health

November 9, 2023 | markets.businessinsider.com

Truist Financial Reaffirms Their Hold Rating on Hims & Hers Health (HIMS)

November 9, 2023 | msn.com

Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know

November 8, 2023 | seekingalpha.com

Hims & Hers: The Most Undervalued Small Cap Stock I See

November 8, 2023 | markets.businessinsider.com

Buy Rating for Hims & Hers Health: Strong Performance and Substantial Growth Potential

November 7, 2023 | forbes.com

Hims Online Therapy Review 2023

November 7, 2023 | barrons.com

Hims & Hers Health Sees Long-Term Tailwind from Weight Management Business

November 7, 2023 | realmoney.thestreet.com

Hims & Hers Health's Outlook Starts to Firm Up

November 7, 2023 | msn.com

Is Hims & Hers Health Stock a Buy After Strong Earnings?

November 7, 2023 | finance.yahoo.com

Hims & Hers Health, Inc. (NYSE:HIMS) Q3 2023 Earnings Call Transcript

November 7, 2023 | seekingalpha.com

Hims & Hers Q3 2023: Another Fantastic Quarter, We're Buying More

November 6, 2023 | seekingalpha.com

Hims & Hers Health, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 6, 2023 | seekingalpha.com

Hims & Hers stock +6% after hours on raised revenue guidance, $50M share buyback

See More Headlines

Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Offices & clinics of medical doctors
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:HIMS
CUSIP: N/A
CIK: 1773751
Web: www.forhims.com
Phone: 415-851-0195
Fax: N/A
Employees: 651
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.08
High Stock Price Target: $18.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +38.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,680,000.00
Net Margins: -4.50%
Pretax Margin: -4.39%
Return on Equity: -11.22%
Return on Assets: -9.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.03
Quick Ratio: 2.76

Sales & Book Value

Annual Sales: $526.92 million
Price / Sales: 3.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.50 per share
Price / Book: 5.83

Miscellaneous

Outstanding Shares: 211,990,000
Free Float: 144,940,000
Market Cap: $1.85 billion
Optionable: Optionable
Beta: 0.78

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Andrew Dudum (Age 34)
Co-Founder, Chairman & CEO
Comp: $1.7M
Mr. Yemi Okupe (Age 37)
Chief Financial Officer
Comp: $804.05k
Ms. Melissa Baird (Age 45)
Chief Operating Officer
Comp: $917.67k
Ms. Irene A. Becklund (Age 38)
Senior VP, Controller & Principal Accounting Officer
Comp: $361.12k
Ms. Soleil Teubner Boughton (Age 44)
Chief Legal Officer & Corporate Secretary
Comp: $782.66k
Mr. Mike Chi (Age 43)
Chief Marketing Officer
Comp: $514.77k
Dr. Patrick Carroll M.D. (Age 65)
Chief Medical Officer, Member of Medical Advisory Board & Director
Comp: $27.03k
Ms. Khobi Brooklyn
Chief Communications Officer
Ms. Amee Parekh
Senior Vice President of Human Resources
Dr. Peter Stahl M.D.
Senior VP & Member of Medical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HIMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings or view top-rated stocks.
What is Hims & Hers Health's stock price target for 2024?: 9 brokers have issued twelve-month price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.08 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts.
How have HIMS shares performed in 2023?: Hims & Hers Health's stock was trading at $6.41 at the start of the year. Since then, HIMS stock has increased by 37.3% and is now trading at $8.80.
View the best growth stocks for 2023 here.
When is Hims & Hers Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our HIMS earnings forecast.

How were Hims & Hers Health's earnings last quarter?: Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $226.70 million for the quarter, compared to analyst estimates of $220.08 million. Hims & Hers Health had a negative net margin of 4.50% and a negative trailing twelve-month return on equity of 11.22%. Hims & Hers Health's revenue for the quarter was up 56.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS.
What ETFs hold Hims & Hers Health's stock?: ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Amplify Online Retail ETF (IBUY), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).
Who are Hims & Hers Health's major shareholders?: Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Institutional Venture Management XVI LLC (3.66%), Institutional Venture Management XV LLC (3.66%), Jupiter Asset Management Ltd. (0.69%), Charles Schwab Investment Management Inc. (0.60%), Northern Trust Corp (0.55%) and Federated Hermes Inc. (0.49%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends.
How do I buy shares of Hims & Hers Health?: Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:HIMS) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial